AGÕæÈ˹ٷ½

Cardlytics, Inc. (CDLX) � Form 4 insider activity for CEO Amit Gupta

On July 1 2025 Mr. Gupta acquired 14,349 common shares through the conversion of restricted stock units (code “M�). The RSUs are part of a previously disclosed 114,796-unit award that vests in eight equal quarterly installments from July 1 2024 through April 1 2026.

On July 2 2025 he sold 6,725 shares at a weighted-average price of $1.7826 solely to cover tax-withholding obligations associated with the vesting event. No other purpose for the sale was indicated.

After the transactions Mr. Gupta directly owns 378,704 common shares and retains 43,049 unvested RSUs. Net of the tax sale, his direct equity stake increased by 7,624 shares.

The activity does not involve new option grants, cash compensation or changes to company fundamentals; it is a routine vesting-and-withholding event that modestly raises the CEO’s long-term exposure to the stock.

Cardlytics, Inc. (CDLX) â€� Form 4 insider filing for CFO Alexis DeSieno

The filing discloses routine equity activity related to previously granted restricted stock units (RSUs). On 1 July 2025, 14,349 RSUs vested and were converted into an equal number of common shares (transaction code “M�). Immediately after vesting, the CFO beneficially owned 179,182 common shares.

On 2 July 2025, the CFO executed a sale of 7,324 shares (transaction code “S�) at a weighted-average price of $1.7826 to cover tax-withholding obligations associated with the RSU delivery. Post-sale, direct ownership stands at 171,858 common shares.

The RSU award originally covered 114,796 shares and vests in eight equal quarterly instalments from 1 July 2024 through 1 April 2026, conditional on continued employment. Following the reported transactions, 43,049 RSUs remain outstanding and unexercised.

• No open-market purchase or discretionary sale occurred beyond the withholding-related disposition.
• The transactions do not change the CFO’s executive status; they are standard Section 16 reporting items.

Implications for investors: The activity appears administrative and tax-related, signalling neither bullish nor bearish intent. Nevertheless, it provides updated visibility into insider holdings and confirms continued service of the CFO, whose remaining share and RSU position maintains alignment with shareholder interests.

Cardlytics, Inc. (CDLX) â€� Form 4 insider transaction: Chief Legal & Privacy Officer Nicholas Hollmeyer reported the vesting of three restricted-stock-unit (RSU) tranches on 01-Jul-2025, converting a total of 12,788 shares of CDLX common stock. On 02-Jul-2025 he sold 5,271 shares at a weighted-average price of $1.7826 per share. According to the filing, the sale was executed solely to satisfy tax-withholding obligations generated by the RSU delivery.

Following the transactions, Hollmeyer’s direct ownership stands at 109,636 common shares. He also retains 39,945 unvested RSUs across three awards that continue to vest quarterly through 01-Apr-2026. No other insider relationships or indirect holdings were disclosed.

The activity represents a routine equity compensation event rather than a discretionary sale. The net effect is a modest increase in the executive’s equity exposure (shares acquired minus shares sold equals +7,517). Given CDLX’s low absolute share price, the dollar value of the tax-sale (~$9.4 k) is immaterial to the company and is unlikely to influence the investment thesis.

Hawaiian Electric Industries, Inc. (HE) filed a Form 4 disclosing that non-employee director Thomas B. Fargo received 11,759 shares of common stock on 06/30/2025. The shares were issued at $0 under the company’s 2011 Non-Employee Director Stock Plan, indicating a routine equity grant rather than an open-market purchase. Following the grant, Fargo’s total beneficial ownership stands at 51,474 shares, broken down as:

• 11,759 shares held directly
• 28,330 shares held indirectly through the Sarah C. Fargo Trust
• 11,385 shares held indirectly through the Thomas B. Fargo Trust

No derivative securities were reported and no sales occurred. While the transaction does not involve cash outlay by the director, additional share ownership may strengthen alignment between board oversight and shareholder interests. The filing was signed on 07/02/2025 by attorney-in-fact Sean K. Clark.

On 2 July 2025, Enstar Group Limited (“Enstar”) filed seven Post-Effective Amendments to Form S-8 registration statements to deregister all unsold ordinary shares that had been reserved for employee and director equity plans. The affected authorisations originally covered approximately 3.16 million ordinary shares across the following programmes:

• 1,200,000 shares â€� 2006 Equity Incentive Plan (Reg. No. 333-141793)
• 460,949 shares â€� 1997 Omnibus Incentive Plan and 29,422 shares â€� 2001 Outside Directors Stock Option Plan (Reg. No. 333-148862)
• 97,862 shares â€� Deferred Compensation Plan for Non-Employee Directors (Reg. No. 333-148863)
• 200,000 shares â€� Employee Share Purchase Plan (Reg. No. 333-149551)
• 689,654 shares â€� 2016 Equity Incentive Plan (Reg. No. 333-212131)
• 84,370 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-237259)
• 400,000 shares â€� A&R 2016 Equity Incentive Plan (Reg. No. 333-265567)

The amendments were triggered by the completion of a merger agreement dated 29 July 2024 under which Enstar survived a series of transactions and became a wholly-owned subsidiary of Elk Bidco Limited. As no further public issuances will occur, Enstar is terminating the effectiveness of the S-8 registrations in accordance with undertakings contained in each filing. The submission is administrative and contains no new financial results. The document was signed in Hamilton, Bermuda by General Counsel Audrey B. Taranto.

Form 4 insider filing � Fiserv, Inc. (FI)

On 30 June 2025, director Charlotte Yarkoni elected to defer US$32,500 of board fees under Fiserv’s Non-Employee Director Deferred Compensation Plan. In exchange, she received 189 deferred-compensation notional units, calculated at the same-day closing share price of $172.41. Each unit represents the right to receive one share of Fiserv common stock after her board tenure ends.

• Transaction code: A (acquisition, non-open-market)
• Units acquired: 189
• Implied value: $32,500
• Post-transaction holdings: 1,100 notional units (direct ownership)
• Settlement: 1-for-1 share conversion upon separation

The filing reports no sales, option exercises, or other derivative activity. Because the transaction stems from fee deferral rather than discretionary share purchases, it does not signal a valuation call, yet it marginally increases equity alignment between the director and shareholders. Given Fiserv’s multibillion-dollar market capitalisation, the dollar value is immaterial to earnings or valuation models and is unlikely to affect trading sentiment. Investors may view the steady use of the deferred-fee program as normal governance practice rather than a catalyst.

Cardlytics, Inc. (CDLX) â€� Form 144 filing indicates an insider intends to sell 5,271 common shares on or about 02-Jul-2025 through Fidelity Brokerage on Nasdaq. The proposed sale represents â‰�0.01&²Ô²ú²õ±è;% of the company’s 52.5 million shares outstanding and carries an estimated market value of $9,396.

The filer—identified in the past-sales section as Nicholas Lynton—previously sold 6,057 shares in two transactions during April 2025, generating gross proceeds of $10,852. The shares to be sold were acquired via restricted-stock vesting on 01-Jul-2025 and are being disposed of for personal account purposes; no cash outlay was involved in the acquisition (classified as compensation).

Because the volume is immaterial relative to the float and no undisclosed adverse information is asserted, the filing is generally routine. Nonetheless, it signals continued insider selling within a three-month window, which investors may monitor for sentiment trends rather than fundamental impact.

Cardlytics, Inc. (CDLX) � Form 4 insider transaction filing

On 06/23/2025 the company granted its Chief Financial Officer, Alexis DeSieno, 40,000 restricted stock units (RSUs) and 15,000 performance stock units (PSUs). The awards were reported under transaction code “A� (grant) and carry a $0 exercise price, meaning they are issued at no cash cost to the executive.

The RSUs vest 50 % on 06/23/2026; the remaining 50 % vests in equal quarterly installments through 06/23/2027, subject to continued employment. The PSUs vest in specified percentages once undisclosed share-price hurdles are met, also contingent on employment. Following the grant, DeSieno beneficially owns 40,000 RSUs and 15,000 PSUs, all held directly.

Because the filing reflects equity compensation rather than an open-market purchase or sale, it does not alter immediate cash flows or signal a directional view on the stock. Nonetheless, the multi-year, performance-linked structure strengthens management alignment with long-term shareholder value while introducing potential future dilution of up to 55,000 shares.

Cardlytics, Inc. (CDLX) â€� Form 4 insider filing dated 06/25/2025 details an equity award to Chief Legal & Privacy Officer Nicholas Hollmeyer Lynton.

Derivative securities granted:

• 25,000 Restricted Stock Units (RSUs) awarded on 06/23/2025. The grant carries no exercise price.
• 9,375 Performance Stock Units (PSUs) awarded on the same date, also at a zero cost basis.

Vesting terms:

• RSUs â€� 50 % vest on 06/23/2026; the balance vests in equal quarterly instalments through 06/23/2027, contingent upon continued employment.
• PSUs â€� Vest in specified brackets only upon achievement of undisclosed share-price targets, and require continued employment on the applicable vesting dates.

Post-transaction ownership: The officer now directly holds 25,000 RSUs and 9,375 PSUs, each convertible into one share of common stock upon vesting, giving potential ownership of 34,375 additional common shares.

Key takeaways for investors: The filing reflects a routine equity incentive grant rather than an open-market purchase or sale; therefore, it does not immediately alter the company’s share count or insider ownership percentages. The inclusion of PSUs tied to price targets signals performance alignment between the executive and shareholders, but the ultimate dilution impact will depend on future vesting and share-price performance.